KOL

Grwth Army Launches in Partnership with GDA Capital to Revolutionize Web3 Growth Marketing and Investment

Retrieved on: 
Tuesday, March 5, 2024

"Our joint venture with GDA Capital embodies our mutual commitment to harnessing the full spectrum of marketing capabilities to revolutionize the web 3.0 space.

Key Points: 
  • "Our joint venture with GDA Capital embodies our mutual commitment to harnessing the full spectrum of marketing capabilities to revolutionize the web 3.0 space.
  • The partnership with GDA Capital brings a wealth of experience and expertise to Grwth Army.
  • GDA Capital's proven track record in digital asset investment and capital markets advisory services complements Grwth Army's focus on KOL-driven marketing distribution and growth strategies.
  • "GDA Capital has always been at the forefront of innovation in the digital asset space," said Michael Gord, Founder at GDA Capital.

Bio-Path Holdings Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Key Points: 
  • “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
  • As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
  • Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
  • ET to review these full-year 2023 financial results and to provide a general update on the Company.

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Retrieved on: 
Thursday, March 7, 2024

The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).

Key Points: 
  • The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).
  • The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics.
  • The event will also highlight oral difelikefalin in NP and its potential in this underserved neuropathy.
  • A live webcast of the event will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com .

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024

The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.

Key Points: 
  • The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
  • With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
  • Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
  • The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Monday, February 26, 2024

“We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.

Key Points: 
  • “We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
  • We remain encouraged to see that no relapses have occurred to date in treated patients, four of whom have been on the study for over ten months.
  • Unfortunately, roughly 40% of patients relapse following HCT, at which point there are limited treatment options and a poor prognosis.
  • A replay will be made available on the “ Events and Presentations ” section of the Company’s investor relations website at ir.tscan.com .

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Retrieved on: 
Tuesday, February 20, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.
  • To register, click here.
  • During the event, Dr. Harrison will also discuss some of the key differentiating features of ALG-055009, a next generation thyroid hormone beta agonist.
  • A live question and answer will follow the formal presentation.

Anti-Integrin Agents Market Research Report 2024: In-Depth Analysis on Size, Target Population, Competitive Landscape and Forecast to 2034 - Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024

The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This detailed publication offers critical insights into the current and future landscape of Anti-integrin Agents, covering the gamut from existing treatments to emerging therapies.
  • The report delves into the competitive landscape of individual therapies, the patient pool eligible for Anti-integrin therapy, and also examines the market share of these treatments.
  • Strategic Market Forecast: Forecasted market trends propelling the Anti-integrin Agents market will equip stakeholders with key knowledge, aiding in strategic decision-making.

China's Liquor Circulation Giant Jiuxian Group: GMV May Reach 10 Billion, Leading the Reform of China's Liquor Industry

Retrieved on: 
Tuesday, February 27, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240226212765/en/
    Jiuxian Group won the honor of "the first brand value of Chinese liquor circulation" in Huazun Cup for 8 consecutive years.
  • Behind this honor is Jiuxian Group's ultimate pursuit of quality, keen insight into market trends and accurate grasp of consumer demand.
  • Through the livestreaming, Jiuxian Group not only provided consumers with a more intuitive and vivid shopping experience, but also successfully won many leading livestreamers such as "Jiuxian Lafeige", "Jiuxian Liangge" and "Jiuxian Daliang".
  • In addition, in terms of marketing, Jiuxian Group has also made massive innovations and took the initiative to try.

PayerPro360 - Empowering Pharma/Biotech with Robust Payer Insights

Retrieved on: 
Tuesday, March 5, 2024

HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.

Key Points: 
  • HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.
  • PayerPro360 by Thelansis - Empowering Pharma/Biotech with Robust Payer Insights.
  • PayerPro360 is an innovative and user-friendly AI-based platform developed by Thelansis Knowledge Partners, designed to revolutionize Payer Research.
  • Payer market research and insights generation are integral to pharma decision-making during drug development, premarket launch strategy, and post-marketing activities.